Internal Medicine E, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel and Sackler Faculty of Medicine, Tel-Aviv University, Israel.
Internal Medicine A, Rabin Medical Center, Beilinson Hospital, Petah Tikva, Israel and Sackler faculty of Medicine, Tel-Aviv University, Israel.
Eur J Intern Med. 2019 May;63:34-41. doi: 10.1016/j.ejim.2019.02.009. Epub 2019 Feb 22.
Iron supplementation, is recommended for the treatment of restless legs syndrome (RLS). We gathered evidence for the efficacy and safety of iron supplementation for RLS.
A systematic review and meta-analysis of randomized controlled trials that compared iron supplementation versus no iron for patients with RLS was performed. Multiple databases were searched. The primary outcome was the effect of iron on the International Restless Legs Syndrome score (IRLSS) at 4 weeks after treatment. For dichotomous data, risk ratios (RR) with 95% confidence intervals (CIs) were estimated and pooled. For continuous data, weighted mean differences (WMD) were calculated.
Ten trials fulfilled the inclusion criteria. Iron therapy was associated with a significant decrease of the IRLSS of -3.55 [95% CI (-5.41) - (-1.68)] points and an increase in the percentage of patients with improvement of the IRLSS score, RR of 2.16 [95% CI 1.56-2.98]. IV FCM was associated with improvement in both the IRLSS (WMD of -2.79 (95% CI (-4.62) - (-0.96), 4 trials, I = 0%) and on the RLS-QOL by WMD of 8.67 (95% CI 1.68-15). Iron was associated with an increased rate of adverse events RR 2.04 (95% CI 1.46-2.85), which were not severe and not associated with increased rate of treatment discontinuation.
Iron supplementation is associated with improvement of the IRLSS score. Our meta-analysis supports the use of iron, oral or IV, as effective therapy for patients with RLS. Further studies should assess subgroups of patients most likely to benefit from iron supplementation.
铁补充剂被推荐用于治疗不安腿综合征(RLS)。我们收集了铁补充剂治疗 RLS 的疗效和安全性证据。
对比较铁补充剂与 RLS 患者无铁治疗的随机对照试验进行了系统评价和荟萃分析。检索了多个数据库。主要结局是治疗后 4 周时铁对国际不安腿综合征评分(IRLSS)的影响。对于二分类数据,估计并汇总风险比(RR)及其 95%置信区间(CI)。对于连续数据,计算加权均数差(WMD)。
10 项试验符合纳入标准。铁治疗与 IRLSS 显著降低 -3.55[95%CI(-5.41)-(-1.68)]点相关,并且改善 IRLSS 评分的患者比例增加,RR 为 2.16[95%CI 1.56-2.98]。IV FCM 与 IRLSS(WMD-2.79[95%CI(-4.62)-(-0.96),4 项试验,I²=0%]和 RLS-QOL(WMD 8.67[95%CI 1.68-15])的改善均相关。铁与不良反应发生率增加相关,RR 为 2.04[95%CI 1.46-2.85],这些不良反应不严重,与治疗中止率增加无关。
铁补充剂与 IRLSS 评分的改善相关。我们的荟萃分析支持使用铁,口服或静脉,作为 RLS 患者的有效治疗方法。应进一步研究评估最有可能从铁补充剂中获益的患者亚组。